Re Monday's news of the purchase of Catalent by Novo Holdings, the seminal question we needed a more definitive answer to is: What specifically is planned for Catalent as a CDMO? Chief Editor Louis Garguilo got some answers. “Customers have been calling me continuously,” said one Catalent executive he spoke with.
Innovations In ADC Technologies
Examine the drivers behind the recent successes in the clinic, current challenges with development and manufacturing, and what the future might hold for the ADC industry.
cGMP Compliance In A Growing Biologics Market
As biologics manufacturers aim for cGMP compliance, explore the challenges of incorporating cGMP standards and how to foster a culture of product quality throughout all levels of your organization.
Container Closure Integrity Testing
Lonza’s Drug Product Services delivers a holistic approach to DP development that prevents problems early and produces a product that is fit for purpose.
Learn how a reliable and agile partner that enables seamless scalability and accelerated development can help you navigate the journey from research and development to clinical trials and beyond.
OUTSOURCED PHARMA CAPACITY UPDATE
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|Connect With Outsourced Pharma: